Article

Development of antibody surrogates for the treatment of cancers and autoimmune disease.

Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA.
Current opinion in chemical biology (Impact Factor: 7.65). 12/2010; 14(6):721-7. DOI: 10.1016/j.cbpa.2010.07.002
Source: PubMed

ABSTRACT Some therapeutic monoclonal antibodies function by focusing the killing power of the immune system on particular cellular targets, a process known as antibody-dependent cell-mediated cytotoxicity (ADCC). There is considerable interest in developing small-molecule therapeutics that utilize this mechanism of action and so act as a kind of antibody surrogate. Progress and challenges in this interesting field are reviewed here.

0 Followers
 · 
65 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article reports the design, synthesis, and evaluation of a novel class of molecules of intermediate size (approximately 7000 Da), which possess both the targeting and effector functions of antibodies. These compounds-called synthetic antibody mimics targeting prostate cancer (SyAM-Ps)-bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor I, thus eliciting highly selective cancer cell phagocytosis. SyAMs have the potential to combine the advantages of both small-molecule and biologic therapies, and may address many drawbacks associated with available treatments for cancer and other diseases.
    Journal of the American Chemical Society 12/2014; DOI:10.1021/ja509513c · 11.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The TRAILR1/TRAIL system is implicated in the induction of the extrinsic apoptotic pathway and constitutes an emerging target in cancer therapeutics. The objective of this study is to assess lymphoma risk associated with certain polymorphisms in TRAILR1 and TRAIL1 genes. DNA was extracted from 381 subjects (190 lymphoma cases and 191 matched controls) and genotyped for polymorphisms rs20576, rs2230229 and rs20575 in TRAILR1 and rs12488654 in TRAIL gene. In contrast to TRAILR1 polymorphisms, the genotype distribution of rs12488654 in TRAIL gene was different between cases and controls, A allele carriers (CA/AA) being much more common in the cases with different lymphoma types (follicular, 45 %; diffuse large B cell, 45.2 % and Hodgkin lymphomas, 40 %) than in controls (15.7 %) (odds ratio (OR), 3.5; CI, 2.1-5.9; p < 0.001; OR, 3.5; CI, 1.6-7.9; p = 0.001; OR, 2.9; CI, 1.1-7.5; p = 0.027, respectively). This effect was consistently independent of the association with the TRAILR1 polymorphisms studied, as demonstrated by linkage disequilibrium and haplotype analyses. This study is the first one to report an association between a TRAIL polymorphism and lymphoma risk and suggests a possible role of TRAIL in B cell lymphomagenesis.
    Annals of Hematology 08/2013; 93(2). DOI:10.1007/s00277-013-1864-4 · 2.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Synthetic immunology, the development of synthetic systems capable of modulating and/or manipulating immunological functions, represents an emerging field of research with manifold possibilities. One focus of this area has been to create low molecular weight synthetic species, called antibody-recruiting molecules (ARMs), which are capable of enhancing antibody binding to disease-relevant cells or viruses, thus leading to their immune-mediated clearance. This article provides a thorough discussion of contributions in this area, beginning with the history of small-molecule-based technologies for modulating antibody recognition, followed by a systematic review of the various applications of ARM-based strategies. Thus, we describe ARMs capable of targeting cancer, bacteria, and viral pathogens, along with some of the scientific discoveries that have resulted from their development. Research in this area underscores the many exciting possibilities at the interface of organic chemistry and immunobiology and is positioned to advance both basic and clinical science in the years to come.
    ACS Chemical Biology 07/2012; 7(7):1139-51. DOI:10.1021/cb300119g · 5.36 Impact Factor

Preview

Download
0 Downloads
Available from